Docket Number: 037003-0307368 PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In Re the Application of

NABIL HANNA, et al. Group Art Unit: 1642

Application No.: 10/743.739 Examiner: M. Davis

Filed: December 24, 2003 Confirmation No.: 9111

For: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450 Alexandria, VA 22313-1450

Sir

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this annilication.

No item of information contained in the information disclosure statement was cited in a communication from a foreign putent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filting of the information disclosure statement.

# The fee pursuant to 37 CFR 1.17(i)(p).

# Respectfully Submitted,

# PILLSBURY WINTHROP SHAW PITTMAN LLP

/ thomas a cawley ir /

Thomas A. Cawley, Jr., Ph.D. Registration Number 40944 Customer Number: 00909

Date: December 8, 2006 Telephone: (703) 770-7900 Facsimile: (703) 770-7901 P.O. Box 10500 McLean, VA 22102

Lis. Patent and Trademotic Reduction Act of 1995, no persons nin required to respond to a collection of trademotic Reduction Act of 1995, no persons nin required to respond to a collection of information unless a contrale a wall ORMS control of COMMERCE.

Under the Paperson's Reduction Act of 1995, no persons nin required to respond to a collection of information unless a contrale a wall ORMS control or and or a wall ORMS control or a wall of the control o

Substitute for form 14498/PTO					Complete If Known			١		
					Application Number	10/743,739		1		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as mocassary)					Filing Date	12/24/2003 NABIL HANNA		1		
					First Named Inventor			1		
					Art Unit	1642		1		
					Examiner Name	M. Davis		1		
Sheet	T	1	of	1	Attorney Docket Number	037003-0307368		1		
				NON PATE	ENT LITERATURE DOCUMENTS			ı		
Examiner Initials*	Cite No.1									
			papillomavirus -transformed keratinocytes papillomavirus infection," Mol. Carcinog.,							
		EA RORKE, Transforming growth factor-beta 1 (TGF beta 1) enances apoptosis in human papillomavirus type 16-immortalized buman ectocervical epithelial cells," Exp. Cell Res., Vol. 216 ( No. 1), p. 65-72, (Jan 1995).								
						regulation of epidermal growth ell. Res. Vol. 220 ( No. 2), p. 390-39	, (0	t 1995		
						es differentiation in human 70 ( No. 8), p. 5437-5436, (Aug 1996				
	<b></b>									
							ļ	1		

ì				_
ı	Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"EXAMEN" is high of releases to marked extended or not distinct in southwareas with MET (Visit). Date also through classifier of release in the following process of the contraction of